Every single year over 5,000,000 patients fall victim to Idiopathic Pulmonary Fibrosis.*
Source: https://www.ncbi.nlm.nih.gov/pubmed/28122457


RDS2 Solutions is developing promising novel medicines to help and potentially cure these patients.


Learn More

Therapeutic Area

We are developing a drug using Vasoactive Intestinal Peptide (VIP) to cure Idiopathic Pulmonary Fibrosis.

Management Team

Meet our excellent and experienced team guiding through the drug approval and value creation process.

Contact Us

Let's get in touch and work together to save lives and be successful!